Volume 15, Number 9—September 2009
Gordonia sputi Bacteremia
Highlight and copy the desired format.
|EID||Renvoise A, Harle J, Raoult D, Roux V. Gordonia sputi Bacteremia. Emerg Infect Dis. 2009;15(9):1535-1537. https://dx.doi.org/10.3201/eid1509.080903|
|AMA||Renvoise A, Harle J, Raoult D, et al. Gordonia sputi Bacteremia. Emerging Infectious Diseases. 2009;15(9):1535-1537. doi:10.3201/eid1509.080903.|
|APA||Renvoise, A., Harle, J., Raoult, D., & Roux, V. (2009). Gordonia sputi Bacteremia. Emerging Infectious Diseases, 15(9), 1535-1537. https://dx.doi.org/10.3201/eid1509.080903.|
To the Editor: In November 2007, a 69-year-old man with fever was hospitalized at the Northern Hospital in Marseilles, France. He also had diabetes, high blood pressure, and alcohol and tobacco addictions. In September 2007, he had received a diagnosis of laryngeal cancer, which required 2 chemotherapy treatments through a central venous catheter (CVC), the second of which he had received 6 days before his November visit. Prostatic cancer, diagnosed 1.5 years earlier, had been treated by radiotherapy. At the time of the November admission, he had leukopenia (1.77 × 109 leukocytes/L with 0.49 × 109 polymorphonuclear cells/L) and an elevated C-reactive protein level (151 mg/L). The patient was admitted with a preliminary diagnosis of drug-induced febrile granulocytosis; the origin of his fever remained unclear. Blood for culture was first collected from a peripheral vein and on the next day was collected from a peripheral vein and from the CVC. Gram-positive rods grew in the aerobic bottle from the CVC sample. The microorganism was identified by biochemical tests using API Coryne strip (bioMérieux, Marcy-l’Etoile, France) as Rhodococcus spp. (94% similarity). The day after hospital admission, the patient was empirically treated with intravenous ticarcillin-clavulanate, 5 g 3×/day; ciprofloxacin, 200 mg 2×/day; and granulocyte colony–stimulating factor. One day later, fever resolved and the polymorphonuclear cell count was within normal limits. Oral antimicrobial drug therapy was continued for 1 week.
Bacterial identification of the strain was performed by 16S rRNA sequencing. We obtained a 1,464-bp sequence, which was found to differ at only 2 nt positions from that of Gordonia sputi (GenBank accession no. X80634). We concluded that our patient had catheter-related bacteremia caused by G. sputi because he was immunocompromised and had a CVC. We ruled out a contaminant because the organism did not belong to the normal flora of human skin and because fever resolved after treatment with antimicrobial drugs.
The genus Gordona was first described in 1971, for coryneform bacteria isolated from sputum of patients with pulmonary disease or from soil (1). It is a member of the mycolic acid–containing group consisting of genera Corynebacterium, Dietzia, Gordonia, Mycobacterium, Nocardia, Rhodococcus, and Tsukamurella. The genus has been revised several times by rearrangements with the genera Rhodococcus and Nocardia, and the name Gordona was changed to Gordonia in 1997. The genus belongs to suborder Corynebacterineae within the order Actinomycetales and currently contains 27 recognized species; only 7 have been described in human disease. Species are identified by molecular analysis.
Gordonia spp. cause a wide spectrum of disease in humans ( 2–10; Table). Neurologic and vascular infections in immunocompromised and immunocompetent patients have been reported. Cutaneous and respiratory infections, otitis externa, osteitis, and arthritis have reportedly occurred only in immunocompetent patients. Bacteria have most often been isolated from blood samples. Bacteremia has started from underlying disease such as a sequestrated lung (4) or acute cholecystis (5) or has been related to coronary artery surgery (2) and frequently to CVCs (2,3,6). Catheter removal has been recommended for treatment of Gordonia spp. infections in children (6), but the recommendation varied for adults. Six cases of infection in children have been described (6), appearing as bacteremia, ventriculitis, and brain abscess.
Microbiologic diagnosis of Gordonia spp. remains difficult. Biochemical profiles can lead to incorrect identification of isolates as Rhodococcus spp. (2,4–6,9) and sometimes Corynebacterium spp. (3) or Nocardia spp. (6). Identification at the genus and species levels is presently obtained by 16S rRNA sequence comparisons.
No recommendation for antimicrobial drug susceptibility testing has been unanimously approved, but these microorganisms seem to be susceptible to many antimicrobial drugs (6). Previous studies suggest a combination of penicillins and aminoglycosides as a suitable therapy for Gordonia-related bacteremia (3). Carbapenem or fluoroquinolone in combination with an aminoglycoside can also be used (6). Antimicrobial drug susceptibility is similar to that of Rhodococcus spp., for which Gordonia spp. are usually incorrectly identified. However, although vancomycin is often used to treat Rhodococcus spp. infections, in a previous study 11% of Gordonia spp. isolates were resistant (6). Treatment must therefore be evaluated specifically for each patient.
Gordonia spp. are environmental bacteria whose implication in human disease seems to be increasing. Phenotypic identification of bacteria included in this genus is difficult, and they are often poorly identified as Rhodococcus spp. or Corynebacterium spp. Molecular identification of Gordonia spp. by using 16S rRNA gene sequence comparison enables their characterization in human disease because the method is more accurate. The fact that these bacteria are often associated with medical devices highlights their role as nosocomial agents. Gram-positive bacilli must, therefore, not be systematically considered as contaminants, especially if associated with medical devices, and should be thoroughly identified by molecular methods in addition to biochemical tests.
We are grateful to Elena Rydkina for revising the English of the manuscript.
- Tsukamura M. Proposal of a new genus, Gordona, for slightly acid-fast organisms occurring in sputa of patients with pulmonary disease and in soil. J Gen Microbiol. 1971;68:15–24.
- Lesens O, Hansmann Y, Riegel P, Heller R, Benaissa-Djellouli M, Martinot M, Bacteremia and endocarditis caused by a Gordonia species in a patient with a central venous catheter. Emerg Infect Dis. 2000;6:382–5.
- Verma P, Brown JM, Nunez VH, Morey RE, Steigerwalt AG, Pellegrini GJ, Native valve endocarditis due to Gordonia polyisoprenivorans: case report and review of literature of bloodstream infections caused by Gordonia species. J Clin Microbiol. 2006;44:1905–8.
- Sng LH, Koh TH, Toney SR, Floyd M, Butler WR, Tan BH. Bacteremia caused by Gordonia bronchialis in a patient with sequestrated lung. J Clin Microbiol. 2004;42:2870–1.
- Gil-Sande E, Brun-Otero M, Campo-Cerecedo F, Esteban E, Aguilar L, García-de-Lomas J. Etiological misidentification by routine biochemical tests of bacteremia caused by Gordonia terrae infection in the course of an episode of acute cholecystitis. J Clin Microbiol. 2006;44:2645–7.
- Blaschke AJ, Bender J, Byington CL, Korgenski K, Daly J, Petti CA, Gordonia species: emerging pathogens in pediatric patients that are identified by 16S ribosomal RNA gene sequencing. Clin Infect Dis. 2007;45:483–6.
- Werno AM, Anderson TP, Chambers ST, Laird HM, Murdoch DR. Recurrent breast abscess caused by Gordonia bronchialis in an immunocompetent patient. J Clin Microbiol. 2005;43:3009–10.
- Iida S, Taniguchi H, Kageyama A, Yazawa K, Chibana H, Murata S, Gordonia otitidis sp. nov., isolated from a patient with external otitis. Int J Syst Evol Microbiol. 2005;55:1871–6.
- Blanc V, Dalle M, Markarian A, Debunne MV, Duplay E, Rodriguez-Nava V, Gordonia terrae: a difficult-to-diagnose emerging pathogen? J Clin Microbiol. 2007;45:1076–7.
- Jannat-Khah DP, Halsey ES, Lasker BA, Steigerwalt AG, Hinrikson HP, Brown JM. Gordonia araii infection associated with an orthopedic device and review of the literature on medical device-associated Gordonia infections. J Clin Microbiol. 2009;47:499–502.
TableCite This Article
Please use the form below to submit correspondence to the authors or contact them at the following address:
Véronique Roux, Laboratoire de Bactériologie–Virologie, Hôpital de la Timone, CNRS UMR 6020, IFR48, 264 rue Saint-Pierre, 13385 Marseille, CEDEX 05, France;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 07, 2010
- Page last updated: December 07, 2010
- Page last reviewed: December 07, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)